Literature DB >> 10493521

Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa).

J Zhao1, J Richter, U Wagner, B Roth, P Schraml, T Zellweger, D Ackermann, U Schmid, H Moch, M J Mihatsch, T C Gasser, G Sauter.   

Abstract

Almost 70% of urinary bladder neoplasms present as low-grade papillary noninvasive tumors (stage pTa). To determine which genomic alterations can occur in pTa tumors of different grades and to evaluate the prognostic significance of chromosomal imbalances, we analyzed 113 pTa tumors (40 grade 1, 55 grade 2, 18 grade 3) by comparative genomic hybridization. pTaG1 (1.9 +/- 2.0) and pTaG2 (3.1 +/- 2.9) tumors had only few genomic alterations with 9q- (44%), 9p- (36%), and -Y (21%) being most prevalent. Neither the total number of aberrations nor any individual alteration was linked to the risk of recurrence in 95 pTaG1/G2 tumors with clinical follow-up information. pTaG3 tumors were characterized by a high number of alterations (7.7 +/- 4.5; P < 0.0001 for G3 versus G2). Several chromosomal imbalances that have previously been reported to be typical for invasive bladder neoplasms were significantly more frequent in pTaG3 than in pTaG2 tumors, including 2q-, 5p+, 5q-, 6q-, 8p-, 10q-, 18q-, and 20q+. A malfunction of genes at these loci may contribute to the development of high-grade urothelial neoplasias. However, there is no evidence for a direct role of these alterations for development of invasive tumor growth.

Entities:  

Mesh:

Year:  1999        PMID: 10493521

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.

Authors:  Haiping Zhou; Hong-ying Huang; Ellen Shapiro; Herbert Lepor; William C Huang; Moosa Mohammadi; Ian Mohr; Moon-shong Tang; Chuanshu Huang; Xue-ru Wu
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

Review 2.  What we could do now: molecular pathology of bladder cancer.

Authors:  M A Knowles
Journal:  Mol Pathol       Date:  2001-08

3.  The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.

Authors:  I A Sokolova; K C Halling; R B Jenkins; H M Burkhardt; R G Meyer; S A Seelig; W King
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

4.  High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer.

Authors:  J Richter; U Wagner; J Kononen; A Fijan; J Bruderer; U Schmid; D Ackermann; R Maurer; G Alund; H Knönagel; M Rist; K Wilber; M Anabitarte; F Hering; T Hardmeier; A Schönenberger; R Flury; P Jäger; J L Fehr; P Schraml; H Moch; M J Mihatsch; T Gasser; O P Kallioniemi; G Sauter
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

5.  A pilot study of urinary microRNA as a biomarker for urothelial cancer.

Authors:  Jaime Snowdon; Sandy Boag; Harriet Feilotter; Jason Izard; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

6.  Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis.

Authors:  J Zhao; R R de Krijger; D Meier; E J Speel; P Saremaslani; S Muletta-Feurer; C Matter; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

Review 7.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

8.  Urine and bladder washing cytology for detection of urothelial carcinoma: standard test with new possibilities.

Authors:  Margareta Strojan Flezar
Journal:  Radiol Oncol       Date:  2010-09-29       Impact factor: 2.991

9.  Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p.

Authors:  Pontus Eriksson; Mattias Aine; Gottfrid Sjödahl; Johan Staaf; David Lindgren; Mattias Höglund
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

10.  LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling.

Authors:  R Matsuda; H Enokida; T Chiyomaru; N Kikkawa; T Sugimoto; K Kawakami; S Tatarano; H Yoshino; K Toki; Y Uchida; K Kawahara; K Nishiyama; N Seki; M Nakagawa
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.